The herpes zoster vaccine live was approved in New Zealand in 2018 for use in older adults. This self-controlled case-series study uses whole-country electronic health record data to assess the risk of serious adverse events associated with the vaccine, with results supporting its safety.
- James F. Mbinta
- Alex X. Wang
- Colin R. Simpson
